医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Tribogenics Receives Strategic Investment from Nikon

2016年02月04日 PM11:00
このエントリーをはてなブックマークに追加


 

TOKYO & LOS ANGELES

Tribogenics, the inventor of triboluminescence based X-ray technology for industrial, security and scientific applications, announced today that Nikon Americas Inc., a subsidiary company of Nikon Corporation, has made a strategic investment in Tribogenics. Nikon Group’s investment will help speed the commercialization of Tribogenics’ Watson™, hand-held XRF analyzer products, using its proprietary new X-ray technology perfected by scientists at Tribogenics and the University of California, Los Angeles (UCLA).

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160204005531/en/

Dale Fox | CEO, Tribogenics (Photo: Business Wire)

Dale Fox | CEO, Tribogenics (Photo: Business Wire)

Together, Nikon Group and Tribogenics aim to strengthen Watson™ XRF product competitiveness and to develop a strong presence in the non-destructive testing (NDT) market. In recent years, there has been an increasing need for X-ray technology for non-destructive testing. Nikon Group and Tribogenics will work together to expand the sales channel with handheld XRF analyzers, cabinet-type X-ray and CT products.

Both companies will collaborate by sharing information on joint technology, business and marketing development programs. Nikon Group will expand its non-destructive and non-contact testing business. Collaboration with Tribogenics makes it possible to strengthen its X-ray business and to generate new business.

According to Dale Fox, Chief Executive Officer, Tribogenics, “Last year, we first commercialized our technology and deployed Watson™ XRF analyzers to customers in the Western United States. Our value proposition caught on, especially by customers using Watson™ for fast and affordable positive materials identification (PMI) of metals and alloys. Now, together with Nikon Group we will expand our growth to customers across the USA and eventually into the overseas market.

About the Technology

X-rays from friction see the light of day as first products go to the market. Tribogenics has developed a new and better way to make X-rays at a fraction of the cost of current technology, which has seen very little innovation since the turn of the 20th century. Tribogenics’ discovery eliminates the need for a high voltage power supply by using a process similar to static electricity (known as the Triboelectric Effect) to generate X-rays directly in a small source. 12 international patents protect this technology. Tribogenics launched its first products for industrial markets in August last year.

About Tribogenics

Based in Los Angeles, Calif., Tribogenics is a leading innovator of triboluminescence based X-ray technology for industrial, medical, and scientific industries. It’s new Watson™ XRF hand-held analyzers remove the risk of error in manufacturing QA/QC environments by performing non-destructive testing (NDT) and PMI of metals and alloys. Initially, Watson™ is used in scrap metal recycling, metal fabrication, machining and manufacturing products for use in the aerospace, automotive, medical, military, scientific and industrial sectors. Watson™ is the X-ray industry’s first ever sub $10,000, hand-held XRF analyzer. www.tribogenics.com or call 1-855-972-9123.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160204005531/en/

CONTACT

Tribogenics
Stewart Chalmers
Vice President of Marketing
+818-681-3588
stewart@tribogenics.com

同じカテゴリーの記事 

  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report